Ajanta Pharma Q3 FY26: Revenue up 20% to ₹1,375 cr, PAT up 18% to ₹274 cr
Ajanta Pharma reported Q3 FY26 consolidated revenue of ₹1,375 crore, up 20%, and PAT of ₹274 crore, up 18%. For 9M FY26, revenue was ₹4,031 crore (up 16%) and PAT was ₹789 crore (up 14%). US Generics revenue grew 52% to ₹399 crore. The company announced an Earnings Conference Call for January 30, 2026.
The announcement includes strong financial results with significant growth in key metrics like revenue and PAT, alongside positive segment-wise performance, which are material information for investors and likely to impact the stock price.
The company reported strong year-on-year growth in revenue and profit after tax for both the quarter and nine months ended December 31, 2025, along with positive segment performance, particularly in the US Generics and India Branded Generics segments.
Ajanta Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a significant increase in performance compared to the same period last year.
For the third quarter of FY2026, revenue from operations grew by 20% to ₹1,375 crore from ₹1,146 crore in Q3 FY2025. EBITDA stood at ₹382 crore, a 19% increase, with an EBITDA margin of 28%. Profit after tax (PAT) rose by 18% to ₹274 crore from ₹233 crore in the prior year's quarter, with PAT at 20%.
Over the nine months of FY2026, revenue from operations increased by 16% to ₹4,031 crore from ₹3,478 crore in the corresponding period of FY2025. EBITDA for the nine months was ₹1,061 crore, up 10%, representing an EBITDA margin of 26%. Excluding a mark-to-market forex loss of ₹61 crore, the adjusted EBITDA stood at ₹1,123 crore, reflecting a 15% growth and a 28% margin. PAT for the nine months grew by 14% to ₹789 crore from ₹695 crore, with PAT at 20%. The company also maintained healthy financial metrics with ROCE at 34% and RONW at 26%.
Segment-wise, the Branded Generics business showed strong performance, with India contributing ₹409 crore (up 19%), Asia ₹288 crore (down 9%), and Africa ₹230 crore (up 33%) for Q3 FY2026. The US Generic segment saw substantial growth, with revenue at ₹399 crore, a 52% increase. The company highlighted its strong performance in India, exceeding IPM growth by 28%, driven by volume increases and new launches. The company also reported progress in its US generic business with 49 products on shelves and 19 ANDAs awaiting approval.
The Board meeting commenced at 1:30 p.m. and concluded at 3:00 p.m. on January 30, 2026. The company will host an Earnings Conference Call on January 30, 2026, at 4:30 p.m. IST.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.